Market news

DaVita has made Berkshire Hathaway a lot of money. Is Berkshire likely to hold onto the stock?

Detailed price information for Archer Daniels Midland (ADM-N) from The Globe and Mail including charting and trades.

DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.

Paving Career Paths to Economic Mobility NORTHAMPTON, MA / ACCESS Newswire / September 14, 2026 / Sustainable career growth is about unlocking lasting economic mobility and new opportunities to learn and grow as an individual. In an evolving healthcare landscape, is working to empower teammates through intentional, comprehensive support.

NORTHAMPTON, MA / ACCESS Newswire / September 10, 2026 / 2025 marked a proud moment for as we met our goal to power 100% of our global operations with renewable energy. We achieved this by securing multiple virtual power purchase agreements in the US and Europe over the past five years - offsetting our global energy consumption with renewable solar and wind power.

DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.

NORTHAMPTON, MA / ACCESS Newswire / September 8, 2026 / 's care network reaches people in every corner of the U. as well as 14 countries around the world.

NORTHAMPTON, MA / ACCESS Newswire / September 4, 2026 / At , doing the right thing and conducting business activities with the highest standards of ethics is foundational to our culture. We are firmly committed to compliance with our policies and all applicable laws and regulations.

DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.

It's also not in the tech or finance sectors.

DaVita (NYSE:DVA) has expanded its partnership with Humana (NYSE:HUM) through a new value-based care agreement covering more than 10,000 Medicare Advantage members living with chronic kidney disease. The programme, which launched on July 1, targets patients with stages 3B through 5 chronic kidney disease (CKD).

NORTHAMPTON, MA / ACCESS Newswire / August 18, 2026 / Throughout DaVita's 25+ year history, we've led the way in patient-centered kidney care. Our work has played a key role in reducing hospitalizations, extending lifespan and helping propel the kidney ...

DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management attributed this to a mix of operational and industry-specific challenges, including flat treatment volumes and sequential declines in revenue per treatment, primarily due to a less favorable commercial mix and reduced revenue from phosphate binders. CEO Javier Rodriguez emphasized, “Our growth is mainly performance clinical—that expands life,

NORTHAMPTON, MA / ACCESS Newswire / August 12, 2026 /Working Together, Working for Better At DaVita, people are the foundation of our community and the driving force behind our pursuit of a healthier tomorrow for all. Rooted in our identity as a community ...

Though DaVita has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.